VT vs SVT with Aberration: A Quick Interpretation Guide Introduction Distinguishing ventricular tachycardia (VT) vs supraventricular tachycardia (SVT) with aberrancy is a critical skill in electrophysiology and emergency medicine. Misdiagnosis can lead to inappropriate treatment and adverse outcomes. This blog … Read More
Cardiovascular Disease
TIME Trial: Evening versus morning dosing of usual antihypertensives
TIME StudyHypertension Treatment in Morning versus Evening Objective:To determine whether evening dosing of antihypertensive medication improves major cardiovascular outcomes compared to morning dosing in patients with hypertension. Study Design: Participants: Primary Endpoint: Results: Conclusion:Evening dosing of antihypertensive medication did not … Read More
STOPDAPT-2 ACS: Clopidogrel Monotherapy after ACS
Visual Abstract Summary for the STOPDAPT-2 ACS Trial Question Is 1–2 months of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy noninferior to 12 months of DAPT with aspirin and clopidogrel in patients with acute coronary syndromes (ACS)? Design Key … Read More
ARIES-HM3 Trial: Aspirin + VKA in LVAD
Visual Abstract Summary for the ARIES-HM3 Trial Question Can aspirin be safely excluded from an antithrombotic regimen, including a vitamin K antagonist (VKA), in patients with a fully magnetically levitated LVAD, and does this reduce nonsurgical bleeding complications? Design Key … Read More
ATHENA-HF Trial: High-Dose Spironolactone in Acute Heart Failure
The ATHENA-HF trial, published in JAMA Cardiology in 2017, evaluated the efficacy and safety of high-dose spironolactone in patients with acute heart failure (AHF). This was a double-blind, placebo-controlled randomized clinical trial, aiming to assess whether high-dose spironolactone could significantly … Read More
TRISCEND II Trial: Transcatheter Tricuspid Valve Replacement in Severe TR
TRISCEND II Trial: EVOQUE Transcatheter Tricuspid Valve Replacement (TTVR) Severe tricuspid regurgitation (TR) has historically been challenging to treat, with medical therapy offering limited relief. The TRISCEND II trial (2024) marks a significant milestone by assessing the safety and efficacy … Read More
Landmark Clinical Trials of Aldosterone Antagonists
landmark clinical trials focusing on aldosterone antagonists (mineralocorticoid receptor antagonists) like spironolactone and eplerenone, which are commonly used in heart failure and other conditions: 1. RALES (1999) • Title: Randomized Aldactone Evaluation Study • Focus: Heart failure with reduced ejection … Read More
ACE-PROTAVI Trial: Protamine Administration for Bleeding in TAVR
The Impact of Routine Protamine Administration in Transcatheter Aortic Valve Implantation (TAVI): Insights from the ACE-PROTAVI Trial As advancements in heart valve interventions continue, minimizing post-procedural complications remains a top priority for healthcare professionals. One area of growing interest is … Read More
GLAGOV Trial: Evolocumab on CAD Progression
GLAGOV Trial: Effect of Evolocumab on Coronary Disease Progression in Statin-Treated Patients The GLAGOV trial is a double-blind, placebo-controlled, randomized study designed to assess the impact of PCSK9 inhibition with evolocumab on the progression of coronary atherosclerosis in patients already … Read More
VERONICA-Nigeria Trial: Triple-Pill for Hypertension
The VERONICA-Nigeria trial, published in JAMA in 2024, evaluated the efficacy and safety of a low-dose triple-pill protocol (telmisartan, amlodipine, and indapamide) versus a standard-care protocol for managing hypertension in Black African adults. This parallel-group, open-label, randomized controlled trial involved … Read More